374Water Receives Approval for Waste Destruction Services in Orlando
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 6 days ago
0mins
Should l Buy SCWO?
374Water Inc. received approval from the City of Orlando for a license to provide Waste Destruction Services at the Iron Bridge Regional Water Reclamation Facility. The approval follows successful completion of a full-scale AirSCWO demonstration project at the Iron Bridge Facility, which achieved greater than 99.95% destruction of PFAS in biosolids and various wastes streams including Aqueous Film-Forming Foam. The agreement provides for an initial five-year term, with options for two additional five-year extensions.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SCWO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SCWO
About SCWO
374Water Inc. is a global industrial technology and services company. The Company provides solutions to global organic waste destruction/treatment and waste management issues within the municipal, federal, and industrial markets. The Company has developed AirSCWO, a proprietary waste destruction/treatment system which harnesses the power of supercritical water oxidation (SCWO). AirSCWO leverages the properties of water in its supercritical phase (above 374 C and above a barometric pressure of 221 Bar). The supercritical phase of water has properties, which when combined with air, destroys waste by oxidizing organic matter and yielding recoverable energy, minerals, and water. Its AirSCWO technology has treated a variety of non-hazardous and hazardous solid and liquid organic wastes. Its technology can process solid wastes, which can be pre-processed into slurries for treatment, including wastewater sludges and biosolids, spent granular activated carbon, among others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
374Water Secures $2.3M Purchase Order from Garney Construction
- Purchase Order Confirmation: 374Water announced a purchase order with Garney Construction worth $2.3 million, which not only generates immediate revenue but also marks the activation of the next phase of a project, enhancing potential municipal collaboration.
- Significant Financial Impact: The issuance of this order led to a $2.3 million invoice and payment to 374Water, directly improving the company's cash flow situation and supporting funding needs for subsequent projects.
- Management Change: 374Water appointed Daniel Bogar as the new President and CEO, whose extensive industry experience is expected to drive strategic development and enhance market competitiveness.
- Compliance Restoration: 374Water has regained compliance with NASDAQ listing requirements, which will boost investor confidence and potentially attract more capital to support the company's long-term growth.
See More
374Water Appoints New CEO and Board Members
- New CEO Appointment: 374Water appointed Daniel Bogar as President and CEO on Tuesday, bringing over 20 years of executive leadership experience in finance, strategic development, and international operations, most recently serving as President and COO of PowerVerde, which is expected to drive the company's strategic transformation.
- Board Restructuring: Recent discussions with investors led to the appointment of new board members, including Brad Freels, Charles Weiser, and Stephen McKnight, who join existing directors Jim Pawloski and Marc Deshusses, forming a board focused on scaling the deployment of the AirSCWO platform.
- Freels' Background: New board member Freels previously served as Chairman and CEO of Midway, possessing extensive experience in infrastructure development and industrial growth strategy, which is expected to bring new perspectives and resources to the company.
- Diverse Board Composition: Weiser, a veteran executive and CPA, along with McKnight, a real estate investor and operating executive, will enhance the company's governance and strategic execution capabilities through their diverse backgrounds.
See More
374Water Regains Nasdaq Compliance with Minimum Bid Price Requirement
- Compliance Restoration: 374Water has received notification from Nasdaq confirming its compliance with the minimum bid price requirement, indicating that the company's compliance issues are resolved, allowing its stock to continue trading on the Nasdaq Capital Market.
- Price Achievement: The company successfully maintained a closing bid price of $1.00 or more for at least 10 consecutive trading days as of January 9, 2026, meeting Nasdaq's listing rules and avoiding potential delisting risks.
- Historical Context: Previously, 374Water received a notification on January 15, 2025, for failing to maintain the minimum bid price over 30 consecutive trading days, and this restoration signifies the stabilization of the company's stock price.
- Market Impact: This compliance restoration not only boosts investor confidence but may also attract more institutional investors, further enhancing the company's market performance and financing capabilities.
See More
374Water (SCWO) Regains Nasdaq Compliance with 10-Day Bid Price Above $1
- Compliance Regained: 374Water announced it has regained compliance with Nasdaq's minimum bid price requirement, as its shares maintained a closing bid price above $1.00 for 10 consecutive trading days, indicating stability and market confidence.
- Continued Trading: Nasdaq confirmed the company meets Listing Rule 5550(a)(2) and has closed the matter, ensuring that SCWO shares will continue trading on the Nasdaq Capital Market, which enhances investor confidence in its future performance.
- Historical Context: 374Water was previously notified in January 2025 for non-compliance after its shares traded below $1.00 for 30 consecutive business days, and regaining compliance marks a significant recovery for the company in the market.
- Market Reaction: Despite SCWO's stock price dropping 2.32% to $2.52 following the announcement, the news of regained compliance may attract more investor interest, potentially laying the groundwork for future price recovery.
See More
374Water Secures $850K PFAS Project with St. Cloud City
- Project Approval: 374Water has secured an $850K PFAS waste treatment project with the City of St. Cloud, highlighting the company's technological strength in addressing hazardous substances, which is expected to enhance its market share and brand influence.
- Technology Application: The project will utilize 374Water's mobile AirSCWO 1 system to eliminate PFAS in undigested and post-thermal hydrolysis digested biosolids, showcasing its efficiency and reliability in waste treatment.
- Public Partnership: Funded by the Minnesota Environment and Natural Resources Trust Fund, this project underscores the state government's commitment to clean drinking water initiatives, allowing 374Water to enhance its influence in the public sector.
- Future Outlook: Set to commence in April 2026, this project will demonstrate the effectiveness of 374Water's PFAS treatment technology, further driving the company's strategic development in the environmental sector.
See More
Ultragenyx Shares Plunge 42% Following Phase 3 Study Failures for Setrusumab
- Stock Plunge: Ultragenyx Pharmaceutical's shares fell sharply by 42% to $19.84 on Monday, primarily due to the failure of its Phase 3 Orbit and Cosmic studies for setrusumab (UX143) in Osteogenesis Imperfecta, leading to a significant decline in market confidence.
- Clinical Trial Failure: The results from Mereo BioPharma and Ultragenyx indicated that setrusumab did not achieve statistical significance in reducing the annualized clinical fracture rate, which not only impacts the company's short-term financial performance but may also have long-term negative implications for its future R&D investments and market competitiveness.
- Severe Market Reaction: The disappointing trial results raised investor concerns about Ultragenyx's future prospects, resulting in a substantial decrease in its market capitalization, reflecting the high sensitivity of investors to the success or failure of clinical trials in the biopharmaceutical sector.
- Industry Impact: Ultragenyx's failure could have a ripple effect across the biopharmaceutical industry, particularly in the bone metabolism disease space, as investors may adopt a more cautious approach towards similar product developments, potentially affecting financing and R&D strategies of related companies.
See More
374Water Secures $2.3M Purchase Order from Garney Construction
- Purchase Order Confirmation: 374Water announced a purchase order with Garney Construction worth $2.3 million, which not only generates immediate revenue but also marks the activation of the next phase of a project, enhancing potential municipal collaboration.
- Significant Financial Impact: The issuance of this order led to a $2.3 million invoice and payment to 374Water, directly improving the company's cash flow situation and supporting funding needs for subsequent projects.
- Management Change: 374Water appointed Daniel Bogar as the new President and CEO, whose extensive industry experience is expected to drive strategic development and enhance market competitiveness.
- Compliance Restoration: 374Water has regained compliance with NASDAQ listing requirements, which will boost investor confidence and potentially attract more capital to support the company's long-term growth.
See More
374Water Appoints New CEO and Board Members
- New CEO Appointment: 374Water appointed Daniel Bogar as President and CEO on Tuesday, bringing over 20 years of executive leadership experience in finance, strategic development, and international operations, most recently serving as President and COO of PowerVerde, which is expected to drive the company's strategic transformation.
- Board Restructuring: Recent discussions with investors led to the appointment of new board members, including Brad Freels, Charles Weiser, and Stephen McKnight, who join existing directors Jim Pawloski and Marc Deshusses, forming a board focused on scaling the deployment of the AirSCWO platform.
- Freels' Background: New board member Freels previously served as Chairman and CEO of Midway, possessing extensive experience in infrastructure development and industrial growth strategy, which is expected to bring new perspectives and resources to the company.
- Diverse Board Composition: Weiser, a veteran executive and CPA, along with McKnight, a real estate investor and operating executive, will enhance the company's governance and strategic execution capabilities through their diverse backgrounds.
See More
374Water Regains Nasdaq Compliance with Minimum Bid Price Requirement
- Compliance Restoration: 374Water has received notification from Nasdaq confirming its compliance with the minimum bid price requirement, indicating that the company's compliance issues are resolved, allowing its stock to continue trading on the Nasdaq Capital Market.
- Price Achievement: The company successfully maintained a closing bid price of $1.00 or more for at least 10 consecutive trading days as of January 9, 2026, meeting Nasdaq's listing rules and avoiding potential delisting risks.
- Historical Context: Previously, 374Water received a notification on January 15, 2025, for failing to maintain the minimum bid price over 30 consecutive trading days, and this restoration signifies the stabilization of the company's stock price.
- Market Impact: This compliance restoration not only boosts investor confidence but may also attract more institutional investors, further enhancing the company's market performance and financing capabilities.
See More
374Water (SCWO) Regains Nasdaq Compliance with 10-Day Bid Price Above $1
- Compliance Regained: 374Water announced it has regained compliance with Nasdaq's minimum bid price requirement, as its shares maintained a closing bid price above $1.00 for 10 consecutive trading days, indicating stability and market confidence.
- Continued Trading: Nasdaq confirmed the company meets Listing Rule 5550(a)(2) and has closed the matter, ensuring that SCWO shares will continue trading on the Nasdaq Capital Market, which enhances investor confidence in its future performance.
- Historical Context: 374Water was previously notified in January 2025 for non-compliance after its shares traded below $1.00 for 30 consecutive business days, and regaining compliance marks a significant recovery for the company in the market.
- Market Reaction: Despite SCWO's stock price dropping 2.32% to $2.52 following the announcement, the news of regained compliance may attract more investor interest, potentially laying the groundwork for future price recovery.
See More
374Water Secures $850K PFAS Project with St. Cloud City
- Project Approval: 374Water has secured an $850K PFAS waste treatment project with the City of St. Cloud, highlighting the company's technological strength in addressing hazardous substances, which is expected to enhance its market share and brand influence.
- Technology Application: The project will utilize 374Water's mobile AirSCWO 1 system to eliminate PFAS in undigested and post-thermal hydrolysis digested biosolids, showcasing its efficiency and reliability in waste treatment.
- Public Partnership: Funded by the Minnesota Environment and Natural Resources Trust Fund, this project underscores the state government's commitment to clean drinking water initiatives, allowing 374Water to enhance its influence in the public sector.
- Future Outlook: Set to commence in April 2026, this project will demonstrate the effectiveness of 374Water's PFAS treatment technology, further driving the company's strategic development in the environmental sector.
See More
Ultragenyx Shares Plunge 42% Following Phase 3 Study Failures for Setrusumab
- Stock Plunge: Ultragenyx Pharmaceutical's shares fell sharply by 42% to $19.84 on Monday, primarily due to the failure of its Phase 3 Orbit and Cosmic studies for setrusumab (UX143) in Osteogenesis Imperfecta, leading to a significant decline in market confidence.
- Clinical Trial Failure: The results from Mereo BioPharma and Ultragenyx indicated that setrusumab did not achieve statistical significance in reducing the annualized clinical fracture rate, which not only impacts the company's short-term financial performance but may also have long-term negative implications for its future R&D investments and market competitiveness.
- Severe Market Reaction: The disappointing trial results raised investor concerns about Ultragenyx's future prospects, resulting in a substantial decrease in its market capitalization, reflecting the high sensitivity of investors to the success or failure of clinical trials in the biopharmaceutical sector.
- Industry Impact: Ultragenyx's failure could have a ripple effect across the biopharmaceutical industry, particularly in the bone metabolism disease space, as investors may adopt a more cautious approach towards similar product developments, potentially affecting financing and R&D strategies of related companies.
See More
